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Pharmacokinetics in the Infant
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Processes controlling the absorption, distribution, metabolism, excretion, and pharmacologic effects of drugs are likely to be immature or altered in
neonates and infants. Absorption may be affected by differences in gastric pH and stomach emptying rate. Low serum protein concentrations and
higher body water composition can change drug distribution. Drug metabolism enzyme activity is typically reduced in the neonate, but rapidly devel-
ops over the first year of life. Renal excretion mechanisms are low at birth, but mature over a few months. Limited data are available on the pharma-
codynamics of drugs; infants show greater sensitivity to d-tubocurarine. Developmental changes are rapid during the first weeks and months of life,
thus requiring continual modification of drug dosage regimens designed for treating pediatric patients. - Environ Health Perspect 102(Suppl
11):107-1100 (1994)
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Introduction
The safe and effective exposure to thera-
peutic drugs and inadvertant chemicals
during the first year oflife presents unique
challenges to the clinician, pharmacokineti-
cist, and toxicologist because of the rapid
changes in size, body composition, and
organ function of infants during this
period. Ignorance of the unique nature of
drug disposition in the neonate led to such
now preventable tragedies as gray baby syn-
drome from chloramphenicol, congenital
anomalies from thalidomide, and ker-
nicterus from sulfonamides. The area of
pediatric pharmacokinetics has blossomed
since the 1970s, when advances in the
development of sensitive and specific drug
assays began. Pharmacokinetic parameters
such as clearance (CL), volume ofdistribu-
tion (V) and half-life (t112) have been
described for many therapeutic agents used
in the newborn and young infant (1-6)
and numerous reviews are devoted to this
subject (1-12). However, quantitation of
clinical effects and pharmacodynamic
response as modified by development and
disease are areas that have lagged behind
description ofpharmacokinetics in this age
group (10).
The information available on pediatric
pharmacokinetics has demonstrated
significant differences in absorption, distri-
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bution, metabolism, and excretion in pre-
mature neonates, full-term neonates, and
older infants (Table 1). A summary ofthe
major age-related physiologic changes that
impact on drug disposition follows.
Absorption from the
Gastrointestinal Tract
Drugs administered by the oral route must
move to sites ofabsorption and then cross
multiple gastrointestinal (GI) membranes
before they pass into systemic circulation.
Most drugs appear to be absorbed by pas-
sive diffusion, although some drugs and
nutrients are absorbed by an active process
(13). Two major factors affecting the
absorption ofdrugs are pH-dependent pas-
sive diffusion and gastric emptying
(14-17). Both processes demonstrate a
variable but age-related trend from birth
well into infancy and childhood (15,17).
The neutral gastric pH (pH 6-8) at birth is
related to the presence ofamniotic fluid in
the stomach (14). Postnatally, gastric acid
secretory capacity appears after the first 24
to 48 hr oflife and gastric acidity decreases
during the first weeks to months of life
(15). Adult values are approached by 3
months of age. In premature infants, gas-
Table 1. Physiologic difference between neonates and
adults.
Gastric
Output
pH 1
Emptying time T
Percutaneous absorption T
Total body water, % T1
% Extracellular water T
% Intracellular water J1
Adipose tissue .1
Serum albumin
Enzyme capacity
Renal function 1
Receptorsensitivity 'T.
tric pH may remain elevated due to imma-
ture acid secretion (18). This higher gastric
pH may explain the higher serum concen-
trations ofacid-labile drugs such as ampi-
cillin, penicillin, and nafcillin observed in
neonates relative to older children and
adults (19,20).
Delayed absorption of phenobarbital,
phenytoin, acetaminophen, and riboflavin
occurs (13,20,21). The rate ofgastric emp-
tying during the neonatal period is both
variable and prolonged (17). Gestational
age and postnatal age both affect gastric
emptying rate (17) with prolonged empty-
ing times seen in premature infants.
Calculated rates of absorption for pheno-
barbital, digoxin, xylose, and other sub-
stances have demonstrated that although
prolonged gastric emptying is present in
neonates, it does not completely account
for the delays seen in gastric absorption of
these compounds (13). Figure 1 demon-
strates the relationship ofenteral absorption
of phenobarbital to age after a single
weight-adjusted dose in children age 10
days to 1 year. The rate constant, ka,
increases with the age of the child (13).
Age-dependent differences in absorption
rate remain even after stimulation ofintesti-
nal motility. However, they demonstrate a
decreased capacity ofenteral absorption in
neonates; this decrease is attributable to fac-
tors other than decreased gastric emptying
time, and GI motility. Additional physio-
logic activities that are diminished in the
neonate are pancreatic enzyme function and
bile acid secretion (22).
Absorption from
Skin and Muscle
Percutaneous absorption may be drastically
increased in neonates owning to an imma-
ture epidermis and increased skin hydration.
Toxicity because of topical application of
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hexachlorophene (23) and isopropanol
(24), among other agents, has been docu-
mented. Conversely, therapeutic serum
theophylline concentrations can be
obtained in premature infants by applying
theophylline gel to the skin (25). Drug
absorption from an intramuscular site may
be unpredictable and decreased due to
insufficient blood flow, poor muscle tone,
and compromised muscle oxygenation (3).
Variable intramuscular absorption has been
demonstrated for digoxin, gentamicin,
phenobarbital, and diazepam in neonates
(3,26).
Distribution
The distribution of drugs within the body
is influenced most notably by the amount
and character ofplasma proteins, and the
relative size of the fluid, fat, and tissue
compartments of the body. Total body
water, expressed as a percentage of total
bodyweight, is as much as 85% in preterm
and 78% in full-term neonates (27). The
effect ofan increased fraction oftotal body
water is apparent when assessing the phar-
macokinetic parameter-volume ofdistribu-
tion-which relates drug concentration in
plasma to the remaining portions of the
body. Table 2 presents calculated Vs for
various drugs. Drugs which distribute in
parallel with body water content have
higher V values for infants than adults.
Conversely, a lipophilic drug such as
diazepam would have a smallerV in infants.
The binding of drugs to plasma pro-
teins is dependent on multiple factors, all
ofwhich may be immature in the neonate
(4). During this period, plasma albumin,
total protein concentrations, and al-acid
glycoprotein are decreased and do not
approach adult values until about 1 year of
age (28,29). In addition, acid-base distur-
bances, competition for binding sites by
increased circulatory concentrations of
endogenous bilirubin and free fatty acids,
and the qualitatively different albumin seen
during the neonatal period, alone or in
concert, may all affect drug protein bind-
ing (1,4).
Metabolism
Hepatic enzyme activity and plasma/tissue
esterase activity are both reduced during
the neonatal period (3). Most enzymatic
microsomal systems responsible for drug
metabolism are present at birth and their
activities increase with advancing gesta-
tional and postnatal age (3,12,30-32).
Hepatic phase I reactions (i.e., oxidation,
reduction, hydroxylation) develop rapidly
during infancy, with adult capacities
attained by 6 months of life (30-32).
These changes have been documented for
phenobarbital, phenytoin, diazepam,
meperidine and numerous other agents
(3,33). Drugs subject to a low hepatic
extraction undergo an even further reduc-
tion in metabolism by neonates (4,12).
Phase II conjugation reactions are gen-
erally reduced at birth, although exceptions
have been demonstrated. The conjugation
with glucuronic acid is significantly
depressed at birth, although a well-devel-
oped capability for sulfate conjugation
exists (20). Glycine conjugations are pre-
sent in neonates at levels comparable to
those of adults (31). Enzymatic systems
responsible for theophylline oxidation and
methylation to caffeine are active in prema-
ture neonates; whereas, the development of
enzymes for oxidative demethylation do
not develop for several months of life
(34,35). The variation of theophylline
metabolism observed during the first year
oflife is presented in Figure 2. Data com-
piled from multiple clinical studies con-
ducted in premature neonates, full-term
neonates, and infants during the first year
oflife, shows the interindividual variation
oftheophylline clearance and its increase
with age. The effect of exogenous growth
hormone administration to deficient chil-
dren was associated with a decrease in theo-
phylline half-life in small number of
patients (36).
Esterase activity is depressed to a greater
extent in premature infants than term
infants and does not achieve even term
infant activity for 10 to 12 months postna-
tally. Low esterase activity coupled with a
diminished volume ofdistribution in the
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Figure 1. Relationship of enteral absorption rate
constant (ka) of phenobarbital to age during the first
year of life. Adapted from Heimann (13).
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Figure 2. Plasma clearance of theophylline in relation
to age for premature infancts (P) and during the first
year of life. Data compiled from multiple published
studies (11).
newborn may account for the prolonged
effect oflocal anesthetics seen during deliv-
ery (37).
A factor also to be considered is in utero
exposure to enzyme inducing agents such
as barbiturates, glucocorticoids, caffeine,
and tobacco (12). Prenatal exposure to
these agents may significantly alter the dis-
position ofsuch drugs as diazepam, pheno-
barbital, and phenytoin after birth (12).
Recently, caffeine has been identified as a
sensitive biomarker for development ofthe
P450 monooxygenase system activity (38)
and maturation ofthis system during criti-
cal phases of growth and development
could be mapped. Slower biotransforma-
Table 2. Comparative distribution parameters of drugs in neonates and adults.
Volume ofdistribution, I/kg Protein binding, %
Drug Neonates Adults Changea Neonates Adults Change' References
Gentamicin 0.77-1.62 0.30-0.67 2.5 x1 <10 <10 N/A Assael (8), Milsap et al. (11), Jungbluth et al. (47)
Theophylline 0.20-2.80 0.44-0.50 3 x 1 32-48 53-65 1/3 xI Rane and Wilson (2), Morselli etal. (3), Milsap et al. (11)
Diazepam 1.40-1.82 2.20-2.60 1/3 x J 84 94-98 1/6 xI1 Morselli (1), Morselli et al. (3), Milsap(11)
Phenytoin 1.20-1.40 0.60-0.67 2 x1 75-84 89-92 1/10 x 1 Morselli (1),Raneand Wilson (2), Milsap (11)
5Approximate mean % change compared to adultvalue.
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tion ofmetronidazole, a drug metabolized
by P450 enzyme system, has been demon-
strated in severely malnourished infants
and children as compared to the nonmal-
nourished state (39).
Renal Excretion
Significant age-dependent changes in renal
function affect the elimination of drugs
and their metabolites. At birth, glomerular
function is more advanced than tubular
function and this persists until 6 months of
age (40-42). The processes ofglomerular
filtration, tubular secretion, and tubular
reabsorption all define the efficiency with
which the kidney eliminates such drugs as
tobramycin (43), netilmicin (44),
mezlocillin (45), gentamicin (46), and
such other agents as glucose, phosphate,
and bicarbonate (11,40). All ofthese clear-
ances may be reduced during infancy. At
birth, glomerular filtration rate (GFR) is 2
to 4 ml/min in term neonates and as low as
0.6 to 0.8 ml/min in prematures (40-42).
Dramatic increases occur during the first
72 hr oflife where GFR may increase 4-
fold (40-42). In general, the renal clear-
ance of drugs that parallel GFR, such as
the aminoglycosides, will exhibit pharma-
cokinetic changes consistent with matura-
tion of renal function, an age dependent
process. A strong relationship has been
demonstrated between mezlocillin CL and
body weight (45) (Figure 3). Further
investigation has revealed that nonrenal
clearance ofthe antibiotic also occurs (47).
Pharmacodynamics and
Receptor Sensitivity
Recent technological developments have
enabled the characterization ofcholinergic,
adrenegic, glucocorticoid, opiate, and hist-
amine receptors (11,48-51). Age-related
alterations in ,-receptor affinity for
adrenegic agonists has been demonstrated
in the elderly (49). The different sensitivity
of the neuromuscular junction to d-
tubocurarine (d-TC) among neonates,
infants, and children and adults has been
determined (52). In addition to the phar-
macodynamic response, the pharmacoki-
netics were also assessed. Figure 4 presents
a summary of the age-dependent variables
of CL, V, t1/2 and d-tubocurarine plasma
concentration required to produce 50%
paralyses. Although plasma clearance
appeared not to change with age, half-life
was prolonged due to the larger V. The
distribution of d-TC parallels that of a
molecule that distributes to extracellular
fluid. The plasma concentration d-TC that
correlates with 50% response was
significantly lower in neonates and infants
than children and adults. Receptor sensitiv-
ity at the neuromuscular blockade appears
then to be increased with paralysis occurring
at alower concentration in this age group.
Data available on receptor sensitivity
during the neonatal period is limited.
Extrapolation from in vitro data may not
be reflective ofthe true pharmacodynamic
response, although data from isolated tissue
preparations provide relevant information
regarding developmental and maturational
changes in receptor binding characteristics.
Drug Monitoring
Pharmacologic and toxicologic assessment
during the neonatal period and throughout
infancy should appreciate not only the
serum drug concentration as an index of
xenobiotic exposure, but also the stage of
development of organ function and body
composition (53-55). Neonates represent
the most fragile group due to their physio-
logical instabilities and their increased
potential for toxic effects.
In conclusion, it is readily apparent that
most ofthe physiologic variables influenc-
ing drug disposition are unique in the
neonate and infant as compared to chil-
dren and adults. This age group should
remain an active population for concern in
future pharmacokinetic, pharmacody-
namic, and toxicologic research.
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Figure 3. Mezlocillin clearance in relation to gesta-
tional age in infants less than 1 week of age. Clearance
values for adults are shown for comparison. From
Janicke et al. (45).
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Figure 4. Pharmacokinetic and pharmacodynamic data
from neonates, infants, children, and adults following
d-tubocurarine infusion. From Fisher at al. (52).
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